---
input_text: Pharmacological management of prolonged seizures in Dravet syndrome including
  intravenous phenytoin. Dravet syndrome (DS) is an infantile onset developmental
  and epileptic encephalopathy. Sodium channel blockers are known to exacerbate seizures
  in this syndrome. Due to its high incidence, the management of prolonged seizures
  is crucial for DS patients. There is still ambiguity regarding the use of intravenous
  phenytoin for prolonged seizure in DS patients mainly due to the lack of data, raising
  concern about the safety of it use. We conducted a retrospective study (from January
  2009 to January 2020) aiming to assess the management of prolonged seizures in DS
  with a focus on the use of intravenous phenytoin. Data were collected for patients
  admitted to our hospital for seizures lasting >5 min. Among 52 identified patients
  in our database, 23 experienced 59 prolonged seizures managed in our hospital. Only
  four seizures ceased without rescue medication. Notably, the use of intravenous
  phenytoin was not associated with discernible adverse effects and was effective
  in stopping status epilepticus in 71% of cases. This study suggests the safety and
  efficacy of intravenous phenytoin for prolonged seizure in DS. There is a need for
  broader investigations of emergency treatments for evidence-based recommendations
  for the emergency plan of each patient.
raw_completion_output: |-
  primary_disease: Dravet syndrome
  medical_actions: Pharmacological management of prolonged seizures; Use of intravenous phenytoin
  symptoms: Prolonged seizures; Status epilepticus
  chemicals: Phenytoin
  action_annotation_relationships: Pharmacological management of prolonged seizures PREVENTS Prolonged seizures IN Dravet syndrome; Use of intravenous phenytoin (with Phenytoin) TREATS Status epilepticus IN Dravet syndrome
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Use of intravenous phenytoin (with Phenytoin) TREATS Status epilepticus IN Dravet syndrome

  ===

extracted_object:
  primary_disease: MONDO:0100135
  medical_actions:
    - Pharmacological management of prolonged seizures
    - Use of intravenous phenytoin
  symptoms:
    - HP:0002133
    - HP:0002133
  chemicals:
    - CHEBI:8107
  action_annotation_relationships:
    - subject: <Pharmacological management of prolonged seizures>
      predicate: <PREVENTS>
      object: <Prolonged seizures>
      qualifier: <Dravet syndrome>
      subject_qualifier: <>
      object_qualifier: <>
      subject_extension: <Pharmacological management>
      object_extension: <Prolonged seizures>
    - subject: Use of intravenous phenytoin
      predicate: TREATS
      object: HP:0002133
      qualifier: MONDO:0100135
      subject_qualifier: with Phenytoin
      subject_extension: CHEBI:8107
named_entities:
  - id: MONDO:0100135
    label: Dravet syndrome
  - id: MAXO:0001187
    label: hysteroscopy
  - id: CHEBI:44915
    label: propofol
  - id: CHEBI:119915
    label: fentanyl
  - id: CHEBI:9130
    label: sevoflurane
  - id: HP:0001250
    label: seizures
  - id: CHEBI:6443
    label: Mirena
  - id: MONDO:0002602
    label: Central nervous system diseases
  - id: HP:0002011
    label: central nervous system diseases
  - id: MONDO:0005027
    label: Epilepsy
  - id: HP:0002014
    label: Diarrhea
  - id: HP:0000988
    label: Rash
  - id: CHEBI:228488
    label: Stiripentol
  - id: CHEBI:60654
    label: Valproate
  - id: CHEBI:69478
    label: Cannabidiol
  - id: CHEBI:80634
    label: 2-propyl-4-pentenoic acid (4-ene-VPA)
  - id: HP:0002373
    label: Febrile seizures
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:31413
    label: clobazam (CLB)
  - id: HP:0010819
    label: drop seizures
  - id: HP:0002329
    label: somnolence
  - id: HP:0004396
    label: decreased appetite
  - id: CHEBI:9925
    label: sodium valproate
  - id: MONDO:0016532
    label: Lennox-Gastaut syndrome
  - id: HP:0000729
    label: Autistic behaviors
  - id: HP:0033258
    label: Sudden unexpected death in epilepsy
  - id: MAXO:0001001
    label: Gene therapy
  - id: MONDO:0002125
    label: Status epilepticus
  - id: HP:0032656
    label: Febrile status epilepticus
  - id: MAXO:0001017
    label: vaccination
  - id: HP:0002069
    label: Generalized tonic-clonic seizure
  - id: CHEBI:3359
    label: CBDA
  - id: CHEBI:167557
    label: CBCA
  - id: CHEBI:66964
    label: Delta9-tetrahydrocannabinol (THC)
  - id: CHEBI:39867
    label: Valproic acid
  - id: CHEBI:5000
    label: Fenfluramine
  - id: HP:0033349
    label: recurrent seizures
  - id: MAXO:0000058
    label: Drug treatment
  - id: HP:0020219
    label: motor seizures
  - id: CHEBI:76720
    label: Antisense oligonucleotides
  - id: MAXO:0001593
    label: ASO therapy
  - id: HP:0012378
    label: Fatigue
  - id: HP:0001945
    label: Pyrexia
  - id: HP:0001654
    label: valvular heart disease
  - id: HP:0002092
    label: pulmonary arterial hypertension
  - id: HP:0002133
    label: Status epilepticus
  - id: CHEBI:17115
    label: vaccine(s)
  - id: MONDO:0100062
    label: Developmental and/or epileptic encephalopathies (DEE)
  - id: HP:0001260
    label: dysarthria
  - id: HP:0001254
    label: lethargy
  - id: HP:0002315
    label: headache
  - id: CHEBI:233158
    label: soticlestat
  - id: CHEBI:34310
    label: 24S-hydroxycholesterol (24HC)
  - id: CHEBI:9586
    label: Tiagabine
  - id: CHEBI:6437
    label: Levetiracetam
  - id: HP:0000708
    label: behavioral problems
  - id: CHEBI:16113
    label: Cholesterol
  - id: MAXO:0001394
    label: Oral administration
  - id: CHEBI:173124
    label: 2-linoleoyl glycerol (2-LG)
  - id: CHEBI:52392
    label: 2-AG
  - id: CHEBI:2700
    label: anandamide
  - id: CHEBI:52640
    label: N-acylethanolamines
  - id: CHEBI:35623
    label: Anticonvulsants
  - id: MAXO:0000942
    label: Vagus nerve stimulation (VNS)
  - id: HP:0002360
    label: Sleep disturbance
  - id: HP:0001249
    label: Intellectual disability
  - id: HP:0001251
    label: ataxia
  - id: CHEBI:42638
    label: fenfluramine (FFA)
  - id: HP:0032794
    label: Myoclonic seizures
  - id: CHEBI:190616
    label: N-desmethylclobazam
  - id: MONDO:0013801
    label: SCN8A encephalopathy
  - id: HP:0001263
    label: Developmental delay
  - id: HP:0100543
    label: Cognitive impairment
  - id: CHEBI:35493
    label: antipyretics
  - id: MAXO:0000932
    label: Electroencephalography (EEG)
  - id: HP:0002353
    label: EEG abnormalities
  - id: CHEBI:73601
    label: <Ketogenic diet (KD)>
  - id: CHEBI:49575
    label: diazepam
  - id: CHEBI:6931
    label: midazolam
  - id: CHEBI:3756
    label: clonazepam
  - id: CHEBI:22720
    label: Benzodiazepines
  - id: MONDO:0010083
    label: Succinic semialdehyde dehydrogenase deficiency
  - id: HP:0000739
    label: Anxiety
  - id: CHEBI:10127
    label: Zonisamide
  - id: CHEBI:87016
    label: Eslicarbazepine acetate
  - id: CHEBI:135939
    label: Lacosamide
  - id: MONDO:0700092
    label: Neurodevelopmental disorders (NDDs)
  - id: CHEBI:63631
    label: Topiramate
  - id: CHEBI:15858
    label: Bromides
  - id: MAXO:0000127
    label: Genetic testing
  - id: MONDO:0008297
    label: Vaccine proximate seizures (VPS)
  - id: MAXO:0000943
    label: deep brain stimulation (DBS)
  - id: MAXO:0000940
    label: responsive neurostimulation (RNS)
  - id: MONDO:0005071
    label: Neurological disorders
  - id: CHEBI:133053
    label: 7-OH-CBD
  - id: MONDO:0002049
    label: Thrombocytopenia
  - id: HP:0001873
    label: thrombocytopenia
  - id: CHEBI:8107
    label: Phenytoin
